Visceral leishmaniasis in Malta - An 18 year paediatric, population based study

Archives of Disease in Childhood

Volumn 82, Issue 5, 2000, Pages 381-385

  Grech, Victor ^a   Mizzi, Joseph ^a   Mangion, Mariella ^a   Vella, Cecil ^a  

^a ST LUKE S HOSPITAL   (Malta)

Author keywords

Antimony; Antiprotozoal agents; Epidemiology; Leishmaniasis; Retrospective study; Sodium stibogluconate

Indexed keywords

ANTIPROTOZOAL AGENT; STIBOGLUCONATE SODIUM;

ARTICLE; CHILD; CHILDHOOD DISEASE; DOG; ENDEMIC DISEASE; FEVER; HEPATOMEGALY; HOST; HUMAN; INCIDENCE; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALTA; PANCYTOPENIA; PRIORITY JOURNAL; SPLENOMEGALY; VISCERAL LEISHMANIASIS;

ADOLESCENT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE NOTIFICATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEISHMANIASIS, VISCERAL; MALE; MALTA; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0034067157     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.82.5.381     Document Type: Article

References (27)

1. 1 Pearson RD, de Queiroz Sousa A. Leishmania species: visceral, cutaneous and mucosal leishmaniasis. In: Mendell GC, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:2428-41.
2. 2 Leishman WB. On the possibility of the occurrence of trypanosomiasis in India. BMJ 1903;ii:79.
3. 3 World Health Organisation. The leishmaniasics. Technical report series no. 743. Geneva: World Health Organisation, 1990.
4. 4 Fleming AF. Opportunistic infections in AIDS in developed and developing countries. Trans R Soc Trop Med Hyg 1990; 84(suppl 1):1-6.
5. 5 Rosenthal E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995,89:159-62.
6. 6 Pineda JA, Gallardo JA, Macias J, et al. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol 1998;36:2419-22.
7. 7 Guarino A, Castaldo A, Di Martino L, Rubino A, Gaeta GB, Gradoni L. Visceral leishmaniasis in a child with HIV-1 infection. Eur J Pediatr 1994;153:301-2.
8. 8 Fenech FF. Leishmaniasis in Malta and the Mediterranean basin. Ann Trop Med Parasitol 1997;91:747-53.
9. 9 Critien A. Infantile leishmaniasis in Malta. Ann Trop Med Parasitol 1911;5:37.
10. 10 Vella Briffa D. Cutaneous leishmaniasis in the Maltese Islands. Br J Dermatol 1985;113:370-1.
11. 11 Leger N, Marchais R, Mandulo-Leblond G, et al. Les phlebotomes impliques dans le transmission des leishmanioses dans File de Gozo (Malte). Anales de Parastilogies Humaine et comparee 1991;66:33-41.
12. 12 Gradoni L, Gramiccia M, Leger N, et al. Iso-enzye characteristics of Leishmania from man, dog and sandflies in the Maltese Islands. Trans R Soc Trop Med Hyg 1991;85:217-19.
13. 13 Amato-Gauci AJ. The control of leishmaniasis in the Maltese Islands. MFPHM Dissertaton, Malta, 1992.
14. 14 Ornvold K, Carstensen H, Magnussen P, Nielsen MH, Pedersen FK. Kala-azar in a four-year-old child 18 months after brief exposure in Malta. Acta Paediatr Scand 1989;78: 650-2.
15. 15 Central Office of Statistics. Demographic review for the Maltese Islands. Malta: Central Office of Statistics (annual publication).
16. 16 Edwards JH. The recognition and estimation of cyclic trends. Ann Hum Genet 1961;25:83-7.
17. 17 Fleiss JL. Statistical methods for rates and proportions, 2nd edition. New York: John Wiley and Sons, 1981:14-15.
18. 18 Nyakundi PM, Gachihi GS, Muigai RK, et al. Relationship between direct agglutination test and splenic aspirate smear parasite load in visceral leishmaniasis at Baringo District, Kenya. East Afr Med J 1994;71:598-600.
19. 19 Minodier P, Piarroux R, Garnier JM, Unal D, Perrimond H, Dumon H. Pediatric visceral leishmaniasis in southern France. Pediatr Infect Dis J 1998;17:701-4.
20. 20 Debono JE. Kala-azar in infancy. Proc R Soc Med 1947;90:155-8.
21. 21 Herwaldt BI, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
22. 22 World Health Organisation. Control of leishmaniasies. Technical report series no. 701. Geneva: World Health Organisation, 1984.
23. 23 Kemp M, Handman E, Kemp K, et al. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. FEMS Immunol Med Microbiol 1998;20:209-18.
24. 24 Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86:615-66.
25. 25 Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5.
26. 26 Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995;89:219-23.
27. 27 Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352: 1821-3.